The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia.
- Author:
Xiang-ping LI
1
;
Hai-rong GONG
1
;
Shui-ping ZHAO
2
;
Wen-yu HUANG
1
Author Information
- Publication Type:Journal Article
- MeSH: Acute Coronary Syndrome; complications; drug therapy; Aged; Anticholesteremic Agents; therapeutic use; Atorvastatin Calcium; Bezafibrate; therapeutic use; Dyslipidemias; complications; Female; Heptanoic Acids; therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; therapeutic use; Lipids; blood; Lipoproteins; blood; Male; Middle Aged; Pyrroles; therapeutic use; Treatment Outcome
- From: Chinese Journal of Cardiology 2013;41(12):1006-1009
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome(ACS) patients complicating with dyslipedemia.
METHODSOne hundred and four hospitalized patients with established ACS and increased serum triglycerides (TG) levels and/or low serum levels of high density lipoprotein cholesterol (HDL-C) were selected. Except for conventional therapy, the patients were randomly divided into 2 groups: control group (n = 52), treated with atorvastatin 20 mg qn or other statin equivalent to 20 mg atorvastatin; treatment group (n = 52), treated with the same dose statin plus bezafibrate 200 mg bid. The serum levels of total cholesterol (TC), TG, low-density lipoprotein cholesterol (LDL-C) and HDL-C were assessed before and after 6 and 12 weeks treatment, side effects and adverse events were recorded.
RESULTSAfter 6 weeks treatment, the serum levels of TC, TG and LDL-C in two groups were significantly reduced compared to baseline (all P < 0.05), which were further declined after 12 weeks treatment, and the reduction was more significant in treatment group(29.8%, 38.0% and 36.1%, respectively) than in control group(14.7%, 9.8% and 26.7%, respectively) (all P < 0.05). After treatment, the serum levels of HDL-C in the two groups were significantly higher than the baseline levels, especially after 12 weeks treatment (all P < 0.05), and the elevations of HDL-C levels in control group and in treatment group were 19.3% and 24.2%, respectively, but there were no significant difference between the two groups (P > 0.05). After 12 weeks, the rates reaching to target goals of LDL-C, TG, HDL-C, and non-HDL-C levels in the treatment group (69.2%, 88.5%, 92.3%, 46.2% and 65.4%, respectively) were significantly higher than those in the control group (34.6%, 65.4%, 46.2%, 7.7% and 42.3%, respectively, all P < 0.05). No serious side effects were observed in the two groups during the treatment period.
CONCLUSIONThe combined statin and bezafibrate treatment is safe and could increase the ratios of reaching target lipid levels in ACS patients complicating with increased TG and (or) decreased HDL-C.
